Publications

Röth A, Fryzek J, Jiang X, Reichert H, Patel P, Su J, Morales Arias J, Broome CM. 2021. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease. Transfusion 62(1):51-59; doi: 10.1111/trf.16745.

Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC, Lang K, Nelson WW. 2021. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 9:2050312120986733.

Hackshaw A, Cohen SS, Reichert H, Kansal AR, Chung KC, Ofman JJ. 2021. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Brit J Cancer, open access.

Snell Taylor SJ, Nielson CM, Breskin A, Saul B, Yu Y, Alam N, … Kelsh M, et al. 2021. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice. Adv Ther 38(5):2673–2688.

McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen SK, … Kelsh M, et al. 2021. Lessons learned using real-world data to emulate randomized trials: A case study of treatment effectiveness for newly diagnosed immune thrombocytopenia. Clin Pharmacol Ther 110(6):1570–1578; doi: 10.1002/cpt.2399.

Haddadin Z, Rankin DA, Lipworth L, Suh M, McHenry R, Blozinski A, Salib George S, Fernandez KN, Varjabedian R, Spieker AJ, Shepard DS, Halasa NB. 2021. Respiratory virus surveillance in infants across different clinical settings. J Pediat 234:164-171; doi: 10.1016/j.jpeds.2021.03.036.

Vágó EK, Nicholson G, Horváth-Puhó E. Hooda N, Fryzek JP, Su J. 2021. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. Curr Med Res Opin 37(10):1829-1835; doi: 10.1080/03007995.2021.1960494.

Dean R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841.

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(Aug):104969; doi: 10.1016/j.yrtph.2021.104969.

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(August):104969; doi: 10.1016/j.yrtph.2021.104969. PMID: 34089813.